Catalyst Wire Dossier Catalyst Wire Dossier

RINVOQ

Upadacitinib · AbbVie Inc.
Drug timelines are a Plus or Pro feature.

43 regulatory and trial events tracked for RINVOQ, covering 2019-08-16 to 2026-07-15. Get the full timeline:

Most recent: EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

See pricing